Act NOW: Speak Out Against Medtech Tariffs
Submit your comments today
Communicating medtech’s role as an asset to the American economy is critical to protecting our industry from tariffs, and we need your help.
The U.S. Department of Commerce has recently launched an investigation that could implement additional sectoral tariffs, known as “Section 232” tariffs, on our industry. While the Commerce Department considers these tariffs, we have the opportunity to make our voice heard by submitting comments until October 17th.
Medtech manufacturing and innovation is strong in the U.S. However, additional industry-wide tariffs could impact the strong progress our industry has made in creating American jobs, jeopardize patient access to innovative medtech, and increase healthcare costs.
Support American medtech manufacturing and make your voice heard by working with AdvaMed to submit a comment to the Federal Register.
To comment, please complete the form below. We may follow up to make sure your ideas are captured clearly and effectively.
KEY POINTS
When → The medtech industry has until October 17th to present its case directly against unwise industry-wide tariffs.
Key areas of focus for the industry → Please consider highlighting how:
- Your company is investing in American jobs, R&D, and helping to lower costs for American patients.
- U.S.-made medical technologies account for 70 percent of the American market.
- Imports only account for 30% of the US market, come mainly from trusted Allies in Europe and North America, and complement our domestic production.
- U.S. medtech is an economic export powerhouse. Since 2019, medtech jobs have grown at three times the average manufacturing job rate, and medtech manufacturing jobs pay substantially more than other manufacturing jobs.
- Additional tariffs could slow the industry’s growth and harm investment in R&D.
- Tariffs will increase costs for hospitals and patients, particularly at a time when hospitals are already struggling to remain financially viable.